Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients.
Cogent Biosciences has reported significant progress in its clinical trials, including the completion of enrollment in the Phase 3 PEAK trial and the initiation of a Phase 1 trial for CGT-4859. The company also announced a strong cash position of $346 million, sufficient to fund operations into late 2026. Upcoming milestones include the delivery of top-line results from SUMMIT, PEAK, and APEX trials in 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.